[Antiplatelet or anticoagulative strategies after surgical/interventional valve treatment]

Herz. 2018 Feb;43(1):26-33. doi: 10.1007/s00059-017-4646-2.
[Article in German]

Abstract

At the end of August 2017 the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) published new joint guidelines for the treatment of valvular heart disease. These guidelines incorporate the scientific progress since the last version of the guidelines published in 2012. This article reviews current guideline recommendations for antiplatelet and anticoagulative therapy after surgical/interventional treatment of the aortic and mitral valves and discusses the underlying scientific evidence.

Keywords: Anticoagulation; Antiplatelet therapy; Heart valve diseases; Mitral valve replacement; Transcatheter aortic valve implantation.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Aortic Valve / surgery*
  • Dose-Response Relationship, Drug
  • Follow-Up Studies
  • Guidelines as Topic
  • Heart Valve Diseases / surgery*
  • Heart Valve Prosthesis Implantation*
  • Hemorrhage / chemically induced
  • Humans
  • Mitral Valve / surgery*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Thromboembolism / prevention & control

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors